Sigyn Therapeutics (OTCQB:SIGY) appointed Jerry DeCiccio as CFO, succeeding Jeremy Farrell, who was appointed CFO in March of 2022.
Mr. DeCiccio has more than 40 years of financial industry experience, previously serving as CFO/COO at Intech Electromechanical, CFO/COO at GTC Telecom, CFO at Incomnet Communications, President at Cerebain Biotech; and in senior financial roles at Parker Hannifin, Waste Management Inc., and Newport Corp. He was also a member of the board of directors and audit committee for Interplay Entertainment, and GT Data Corp.
Mr. DeCiccio earned a Bachelor of Science degree in accounting and business administration from Loma Linda University and an MBA in finance and systems technology from the University of Southern California. He is also a Certified Public Accountant in California.
In a statement, Jim Joyce, CEO of Sigyn, commented, “we are thrilled to have Jerry join our team as we shift focus toward the clinical advancement of Sigyn Therapy and unlocking the value of our therapeutic pipeline.”
Mr. DeCiccio added, “I believe the potential for value creation is tremendous. Having previously been in positions in similar industries, I am confident that we will further develop and execute our business plan.”
